Roche's Parkinson's failure a blow to researchers; Nexvet pulls off a $40M IPO;

@FierceBiotech: G1 banks $33M to cut in on a blockbuster oncology race. News | Follow @FierceBiotech

@JohnCFierce: Look for more M&A ahead: Pfizer beefs up on biosimilars with $15B Hospira deal. Article | Follow @JohnCFierce

@DamianFierce: $AZN says it's on schedule to submit brodalumab this year and the PD-L1-blocking '4736 in 2016. Picture | Follow @DamianFierce

> Two early-stage Parkinson's disease candidates from Roche ($RHHBY) ran into toxicity issues in preclinical trials, a blow to the hypothesis that blocking the protein LRRK2 can treat the ailment. More

> Animal biotech Nexvet Biopharma raised $40 million in an IPO, pricing below its range. News

Medical Device News

@FierceMedDev: ICYMI yesterday: Boston Scientific CEO touts pipeline during earnings call. Article | Follow @FierceMedDev

@VarunSaxena2: Boston Scientific CEO touts pipeline during earnings call. More | Follow @VarunSaxena2

@EmilyWFierce: Sen. Warren has a bone to pick with pharma, but devicemakers are getting a hall pass. More from Time | Follow @EmilyWFierce

> Two new med tech incubators in the works--one with the AMA, the other Georgia Tech. News

> Medtronic gains first FDA approval for Covidien device: Pipeline Flex for brain aneurysm. Story

> DOJ issues permanent injunction against German devicemaker for violating FDA regs. Report

Pharma News

@FiercePharma: Scientists in search of next-generation #Ebola #vaccines as outbreak dwindles. More | Follow @FiercePharma

@EricPFierce: Hospira says it will be acquired by Pfizer for $17B. Oh and it had another recall too. News | Follow @EricPFierce

@CarlyHFierce: Measles-jab maker Merck says it can only do so much to encourage vaccination. Story | Follow @CarlyHFierce

> Look for a new Sanofi CEO by March, says chairman, as earnings top forecast. News

> FDA chief Hamburg to step down, with new deputy a potential successor. More

> AstraZeneca continues its respiratory land grab with $600M-plus Actavis deal. Article

Vaccines News

> Scientists in search of next-generation Ebola vaccines as outbreak dwindles. Item

> Measles-jab maker Merck says it can only do so much to encourage vaccination. Report

> Takeda drops DTaP/sIPV development to focus on 'higher-impact' programs. More

> Serum Institute gets Genticel's Vaxiclase tech to develop pertussis vaccine. Story

> Astellas joins forces with Immunomics on allergy vaccine. Article

Pharma Manufacturing News

> Hospira issues another recall even as Pfizer announces buyout deal. Story

> Dr. Reddy's expanding capacity at three plants. News

> India's Wockhardt says it has addressed U.S. FDA compliance issues at Illinois plant. More

> U.K. regulators shut down plant making potentially contaminated drug. Story

> Novo investing $750M in manufacturing this year. Article

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.